Highlights Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 12/06/2025 BST			5-day change	1st Jan Change
1,484.00 ^DKK	-0.03%		+3.16%	-0.57%

06-09	Genmab A/S Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08:00 AM
06-09	AlphaValue/Baader Europe Keeps Genmab at Buy, Boosts Price Target on Pipeline Strength	MT

Highlights

AlphaValue/Baader Europe Keeps Genmab at Buy, Boosts Price Target on Pipeline Strength	06-09	MT
GENMAB : Beaten up share price offers an opportunity	06-06
Genmab A/S Announces Investigational Rinatabart Sesutecan (Rina-S) Demonstrates Encouraging Anti-Tumor Activity Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL-01 Trial	06-02	CI
Genmab A/S to Present New and Updated Results from Its Robust Epcoritamab (Epkinly®) Development Program At the 2025 European Hematology Association Congress	05-14	CI
GENMAB : Mixed Q1; guidance maintained	05-10
Genmab Q1 Earnings, Revenue Increase	05-08	MT
Genmab A/S Maintains Earnings Guidance for the Year 2025	05-08	CI
Genmab A/S Reports Earnings Results for the First Quarter Ended March 31, 2025	05-08	CI
Earnings Flash (GMAB) Genmab Posts Q1 EPS $3.05	05-08	MT
Earnings Flash (GMAB) Genmab Posts Q1 Revenue $715M, vs. FactSet Est of $735.9M	05-08	MT
Genmab Says Revenue Was $715 Million For First Three Months Of 2025	05-08	RE
Sector Update: Health Care Stocks Rise Premarket Friday	05-02	MT
Genmab A/S to Submit Supplemental Biologics License Application to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed Refractory Follicular Lymphoma	05-02	CI
Genmab To Submit SBLA To FDA For Epcoritamab Plus Rituximab And Lenalidomide	05-02	RE
Genmab to Seek US FDA Approval for Follicular Lymphoma Therapy Combination Drug	05-02	MT
Genmab Says To Submit SBLA To FDA For Ecoritamab In 2025	05-02	RE
Genmab Announces Q1 Nets Sales Of Darzalex	04-15	RE
Genmab A/S announces an Equity Buyback.	03-31	CI
Genmab's Tivdak Wins Japanese Approval for Cervical Cancer Treatment	03-27	MT
Genmab Says Japan Approves Tivdak for Cervical Cancer	03-27	MT
Genmab A/S Announces Japan Ministry of Health, Labour and Welfare Approves TIVDAK for the Treatment of Advanced or Recurrent Cervical Cancer	03-27	CI
Genmab Announces Repurchase Of Up To 2.2 Million Shares With A Maximum Aggregate Total Value Of Dkk 4 Billion	03-25	RE
Genmab Denies Trade Secret Misappropriation Claims by AbbVie	03-24	MT
Genmab Faces US Lawsuit Over Alleged Trade Secret Misappropriation	03-23	MT
Genmab To Vigorously Defend Alleged Claims Of Trade Secret Misappropriation By Abbvie Inc.	03-22	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GENMAB : Beaten up share price offers an opportunity

June 06, 2025 at 01:40 pm

Genmab: From now on, courage to the most patient

April 01, 2025 at 03:57 pm